ArticleOncoTargets and therapy2023

Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML.

Xiaotong Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.